NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in the United States

Core Viewpoint - NuCana plc has received a new patent for NUC-7738, enhancing its intellectual property protection and supporting its ongoing clinical studies for this novel anti-cancer agent [1][2]. Group 1: Patent and Intellectual Property - The United States Patent and Trademark Office (USPTO) issued a new patent (US12,054,510) for NUC-7738's composition of matter, which is a significant addition to the company's existing portfolio of over 80 issued patents worldwide [1][2]. - The new patent strengthens the intellectual property protection for NUC-7738, which is crucial for the company's competitive positioning in the biopharmaceutical market [2]. Group 2: Clinical Development and Efficacy - NUC-7738 is currently in a Phase 2 clinical study in combination with pembrolizumab for patients with PD-1 inhibitor resistant melanoma, with encouraging data presented at the ESMO Congress 2024 [1][2]. - The majority of patients with PD-1 inhibitor resistant metastatic melanoma achieved a progression-free survival of more than 5 months when treated with NUC-7738 plus pembrolizumab, compared to a median progression-free survival of 2-3 months with the current standard of care [2]. - NUC-7738 targets multiple aspects of the tumor microenvironment, which may contribute to its ability to make previously resistant tumors sensitive to treatment [2]. Group 3: Company Overview and Technology - NuCana is a clinical-stage biopharmaceutical company focused on improving cancer treatment outcomes through its ProTide technology, which transforms conventional chemotherapy agents into more effective and safer medicines [3]. - The company's pipeline includes NUC-3373 and NUC-7738, with NUC-3373 currently being evaluated in multiple clinical studies for various cancer types [3].